| - |
Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride |
Fydrane® |
Is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia, during the surgical procedure. |
Rapid Review Complete |
20th December 2016 |
 |
| - |
Piperaquine tetraphosphate/dihidroartemisinin |
Eurartesim® |
For uncomplicated malaria caused by the Plasmodium falciparum parasite |
Rapid Review Complete |
28th May 2012 |
|
| - |
Pirfenidone |
Esbriet® |
For the treatment of mild to moderate idiopathic pulmonary fibrosis. |
Assessment Process Complete |
20th March 2013 |
|
| - |
Pitavastatin |
Livazo® |
Is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate. |
Rapid Review Complete |
29th December 2010 |
|
| - |
Pitolisant hydrochloride |
Wakix® |
For the treatment of narcolepsy with or without cataplexy and should be initiated by a physician experienced in the treatment of sleep disorders. |
Rapid Review Complete |
15th June 2017 |
|
| 23054 |
Pitolisant hydrochloride |
Wakix® |
Pitolisant hydrochloride (Wakix®) is indicated in adults, adolescents, and children aged 6 years and older for the treatment of narcolepsy with or without cataplexy |
Rapid Review Complete |
4th October 2023 |
|
| - |
Pixantrone |
Pixuvri® |
Is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas (NHL). |
Rapid Review Complete |
20th March 2015 |
|
| 19052 |
Polatuzumab vedotin |
Polivy® |
In combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT). |
Assessment Process Complete |
16th February 2021 |
|
| 22043 |
Polatuzumab vedotin |
Polivy® |
In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). |
NCPE Assessment Process Complete |
5th December 2023 |
|
| - |
Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) |
Velphoro® |
Is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Rapid Review |
Rapid Review Complete |
8th October 2014 |
|
| - |
Pomalidomide |
Imnovid®) |
In combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy. |
Assessment Process Complete |
13th March 2015 |
|
| 22016 |
Pomalidomide |
Imnovid® |
In combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. |
Rapid Review Complete |
5th May 2022 |
|
| - |
Ponatinib |
Iclusig® |
Is indicated for patients in chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation and for Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. |
Assessment Process Complete |
4th January 2016 |
|
| 21036 |
Ponesimod |
Ponvory® |
For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. |
Rapid Review Complete |
8th October 2021 |
|
| - |
Prasugrel |
Efient® |
For the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention. |
Assessment Process Complete |
1st February 2010 |
|
| - |
Pregabalin |
Lyrica® |
For the treatment of Generalised Anxiety Disorder. |
Full HTA Assessment |
15th December 2014 |
|
| - |
Pregabalin |
Lyrica® |
For the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy. |
Full HTA Assessment |
12th June 2015 |
|
| - |
Progesterone (micronised) |
Utrogestan® |
Progesterone (micronised) is indicated in women for supplementation of the luteal phase during ART cycles. |
Rapid Review Complete |
20th November 2019 |
|
| - |
Prucalopride |
Resolor® |
For the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. |
Rapid Review Complete |
29th March 2011 |
|
